Literature DB >> 12892460

Independent predictive value of the overall number of metastatic N1 and N2 stations in lung cancer.

Kazuhiro Ueda1, Yoshikazu Kaneda, Hisashi Sakano, Toshiki Tanaka, Masatarou Hayashi, Tao-Sheng Li, Kimikazu Hamano.   

Abstract

OBJECTIVE: The number of metastatic N2 stations is a known prognostic factor in patients with non-small-cell lung cancer (NSCLC). However, involvement of N1 stations as well as that of N2 stations seems to be important in the prognosis of these patients. We therefore attempt to clarify the significance of the total number of metastatic stations in pathologic N1 and N2 NSCLCs.
METHODS: Patients with either pathologic N1 (n = 51) or N2 (n = 96) NSCLC who had undergone major pulmonary resection with complete mediastinal dissection were included in this retrospective study. All positive nodes were characterized by location according to the TNM classification system. The hilar station was included with the N2 stations.
RESULTS: The total number of metastatic stations in patients with N2 disease ranged from 1 to 8 (average 2.5), whereas that in patients with N1 disease ranged from 1 to 3 (average 1.2). The incidence of multiple-station metastasis (> or = 3 metastatic stations) among N2 patients (35%) was significantly higher than that among N1 patients (2%) (p < 0.001). Multivariate analysis of survival showed pathologic N1 status (relative risk = 0.443, p = 0.013) and < or = 2 metastatic stations (relative risk = 0.515, p = 0.020) to be significant and independent prognostic factors. Age, sex, cell type, resected lobe, and pathological T status were statistically insignificant determinates of survival.
CONCLUSIONS: The total number of metastatic stations (< or = 2 vs > or = 3) is an independent prognostic indicator in patients with completely resected pathologic N1 or N2 NSCLC. The number of metastatic stations will be useful as a stratification factor in prospective clinical trials of these patients.

Entities:  

Mesh:

Year:  2003        PMID: 12892460     DOI: 10.1007/bf02719381

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  8 in total

1.  Intraoperative lymphatic mapping for non-small cell lung cancer: the sentinel node technique.

Authors:  A G Little; A DeHoyos; D M Kirgan; T R Arcomano; K D Murray
Journal:  J Thorac Cardiovasc Surg       Date:  1999-02       Impact factor: 5.209

2.  Regional lymph node classification for lung cancer staging.

Authors:  C F Mountain; C M Dresler
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

3.  The role of surgery in N2 lung cancer.

Authors:  N Martini; B J Flehinger
Journal:  Surg Clin North Am       Date:  1987-10       Impact factor: 2.741

4.  Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials.

Authors:  Y Ichinose; H Kato; T Koike; R Tsuchiya; T Fujisawa; N Shimizu; Y Watanabe; T Mitsudomi; M Yoshimura
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

5.  Lymph node mapping and curability at various levels of metastasis in resected lung cancer.

Authors:  T Naruke; K Suemasu; S Ishikawa
Journal:  J Thorac Cardiovasc Surg       Date:  1978-12       Impact factor: 5.209

6.  Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer.

Authors:  M J Liptay; G A Masters; D J Winchester; B L Edelman; B J Garrido; T R Hirschtritt; R M Perlman; W A Fry
Journal:  Ann Thorac Surg       Date:  2000-08       Impact factor: 4.330

7.  Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications.

Authors:  F Andre; D Grunenwald; J P Pignon; A Dujon; J L Pujol; P Y Brichon; L Brouchet; E Quoix; V Westeel; T Le Chevalier
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  Hilar lymph nodes in N2 disease: survival analysis of patients with non-small cell lung cancers and regional lymph node metastasis.

Authors:  Kazuhiro Ueda; Yoshikazu Kaneda; Kouichi Saeki; Nobuhiro Fujita; Nobuya Zempo; Kensuke Esato
Journal:  Surg Today       Date:  2002       Impact factor: 2.549

  8 in total
  6 in total

1.  Early recurrence of completely resected N2-positive non-small-cell lung cancer.

Authors:  Takuma Tsukioka; Noritoshi Nishiyama; Takashi Iwata; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Kiyotoshi Inoue; Shigefumi Suehiro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-03

2.  Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer.

Authors:  Sirisha Jonnalagadda; Jacqueline Arcinega; Cardinale Smith; Juan P Wisnivesky
Journal:  Cancer       Date:  2011-03-30       Impact factor: 6.860

3.  The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer.

Authors:  Sirisha Jonnalagadda; Cardinale Smith; Grace Mhango; Juan P Wisnivesky
Journal:  Chest       Date:  2011-02-03       Impact factor: 9.410

4.  The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer.

Authors:  Fuqiang Dai; Lunxu Liu; Guowei Che; Nanbin Yu; Qiang Pu; Shangfu Zhang; Junliang Ma; Lin Ma; Zongbing You
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

5.  The role of segmental nodes in the pathological staging of non-small cell lung cancer.

Authors:  Zhen-xuan Li; Hong Yang; Ke-lin She; Ming-xing Zhang; Han-qing Xie; Peng Lin; Lan-jun Zhang; Xiao-dong Li
Journal:  J Cardiothorac Surg       Date:  2013-12-08       Impact factor: 1.637

6.  New TNM staging in lung cancer (8th edition) and future perspectives.

Authors:  José-María Matilla; M Zabaleta; E Martínez-Téllez; J Abal; A Rodríguez-Fuster; J Hernández-Hernández
Journal:  J Clin Transl Res       Date:  2020-09-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.